MA37142A3 - Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine - Google Patents

Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine

Info

Publication number
MA37142A3
MA37142A3 MA37142A MA37142A MA37142A3 MA 37142 A3 MA37142 A3 MA 37142A3 MA 37142 A MA37142 A MA 37142A MA 37142 A MA37142 A MA 37142A MA 37142 A3 MA37142 A3 MA 37142A3
Authority
MA
Morocco
Prior art keywords
oxazine
dihydro
pyrido
benzo
derivatives
Prior art date
Application number
MA37142A
Other languages
English (en)
Other versions
MA37142B1 (fr
MA37142A2 (fr
Inventor
Sylvie Chamoin
Giorgio Caravatti
Pascal Furet
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37142A2 publication Critical patent/MA37142A2/fr
Publication of MA37142A3 publication Critical patent/MA37142A3/fr
Publication of MA37142B1 publication Critical patent/MA37142B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne des composés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine de formule (i) et/ou leurs sels et/ou solvates de qualité pharmaceutique, dans laquelle y, v, w, u, q, r
MA37142A 2011-12-22 2012-12-20 Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine MA37142B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579231P 2011-12-22 2011-12-22
PCT/IB2012/057554 WO2013093849A1 (fr) 2011-12-22 2012-12-20 Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine

Publications (3)

Publication Number Publication Date
MA37142A2 MA37142A2 (fr) 2016-07-29
MA37142A3 true MA37142A3 (fr) 2018-05-31
MA37142B1 MA37142B1 (fr) 2019-07-31

Family

ID=47678928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37142A MA37142B1 (fr) 2011-12-22 2012-12-20 Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine

Country Status (42)

Country Link
US (2) US9539260B2 (fr)
EP (1) EP2794600B1 (fr)
JP (1) JP5903499B2 (fr)
KR (1) KR101656592B1 (fr)
CN (1) CN104011045B (fr)
AP (1) AP4055A (fr)
AR (1) AR089424A1 (fr)
AU (1) AU2012356083B2 (fr)
BR (1) BR112014015103B1 (fr)
CA (1) CA2859764C (fr)
CL (1) CL2014001452A1 (fr)
CO (1) CO6990717A2 (fr)
CR (2) CR20200286A (fr)
CU (1) CU20140072A7 (fr)
CY (1) CY1119939T1 (fr)
DK (1) DK2794600T3 (fr)
EA (1) EA025322B1 (fr)
EC (1) ECSP14009999A (fr)
ES (1) ES2661864T3 (fr)
GT (1) GT201400131A (fr)
HR (1) HRP20180384T1 (fr)
HU (1) HUE036953T2 (fr)
IL (1) IL233117A (fr)
IN (1) IN2014CN04174A (fr)
JO (1) JO3398B1 (fr)
LT (1) LT2794600T (fr)
MA (1) MA37142B1 (fr)
MX (1) MX353342B (fr)
MY (1) MY170922A (fr)
NO (1) NO2809782T3 (fr)
PE (1) PE20141598A1 (fr)
PH (1) PH12014501417B1 (fr)
PL (1) PL2794600T3 (fr)
PT (1) PT2794600T (fr)
RS (1) RS56891B1 (fr)
SG (1) SG11201402237WA (fr)
SI (1) SI2794600T1 (fr)
TN (1) TN2014000210A1 (fr)
TW (1) TWI577674B (fr)
UA (1) UA112558C2 (fr)
UY (1) UY34541A (fr)
WO (1) WO2013093849A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
SG11201402826YA (en) 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
IN2014CN04174A (fr) 2011-12-22 2015-09-04 Novartis Ag
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201422625A (zh) * 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
SI2928896T1 (sl) * 2012-11-26 2017-10-30 Novartis Ag Trdna oblika derivata dihidro-pirido-oksazina
CN105541698B (zh) * 2015-12-23 2018-07-10 滨海康杰化学有限公司 一种5-溴-2-三氟甲基吡啶的制备方法
GB2550437B (en) * 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
CA3085147A1 (fr) * 2017-12-22 2019-06-27 Petra Pharma Corporation Derives de chromenopyridine utilises en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase
RU2769507C1 (ru) 2018-08-13 2022-04-01 Ф. Хоффманн-Ля Рош Аг Новые гетероциклические соединения как ингибиторы моноацилглицеринлипазы
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
KR20220062515A (ko) 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
EP4061821A1 (fr) * 2019-11-20 2022-09-28 F. Hoffmann-La Roche AG Composés de spiro(isobenzofurane azétidine) pour le traitement d'une maladie auto-immune
WO2022013311A1 (fr) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Dérivés de pyrido-oxazine en tant qu'inhibiteurs d'alk5
WO2023170680A1 (fr) 2022-03-08 2023-09-14 Equashield Medical Ltd Station de transfert de fluide dans un système de préparation pharmaceutique robotique
CN116535436B (zh) * 2023-05-06 2024-04-30 遵义医科大学 一种氟离子荧光探针及其合成方法和应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
TW224941B (fr) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (fr) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Derives de quinazoline
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CA2224435C (fr) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines et leurs procedes de preparation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
JP2000512990A (ja) 1996-06-24 2000-10-03 ファイザー・インク 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
CA2265630A1 (fr) 1996-09-13 1998-03-19 Gerald Mcmahon Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (fr) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, de leurs intermediaires et de leurs analogues
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
EP1135470A2 (fr) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Matieres et procedes recombinants destines a la production d'epothilone et de derives d'epothilone
ES2297943T3 (es) 1998-12-23 2008-05-01 Aventis Pharma Limited Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
EP1255743A1 (fr) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINES UTILISEES COMME INHIBITEURS DU FACTEUR Xa
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ535616A (en) 2000-11-07 2006-03-31 Novartis Ag Indolymaleimide derivatives as protein kinase c inhibitors
JPWO2002072049A1 (ja) 2001-02-27 2004-07-02 山之内製薬株式会社 育毛用医薬組成物
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
BR0316386A (pt) 2002-12-06 2005-09-27 Warner Lambert Co Benzoxazin-3-onas e seus derivados como inibidores de p13k
PL376844A1 (pl) 2002-12-09 2006-01-09 The Board Of Regents Of The University Of Texas System Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
EP1581529A1 (fr) 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines et leurs derives en tant qu'inhibiteurs de pi3ks
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1720844B1 (fr) 2003-04-03 2009-04-29 MERCK PATENT GmbH Derives pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl9-phenylamide) et composes similaires pour l'utilisation comme inhibiteurs du facteur xa pour le traitement de maladies thromboemboliques
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
RU2392278C2 (ru) 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
US20090042773A1 (en) 2004-10-12 2009-02-12 Reinhard Wetzker P13 kinase gamma inhibitors for the treatment of anaemia
WO2006050054A2 (fr) 2004-11-01 2006-05-11 Nuada, Llc Composes et methodes d'utilisation de ces composes
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ZA200802080B (en) * 2005-09-07 2009-09-30 Serono Lab P13K inhibitors for the treatment of endometriosis
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
US8242116B2 (en) 2006-06-26 2012-08-14 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
JP2010518107A (ja) * 2007-02-06 2010-05-27 ノバルティス アーゲー Ｐｉ３−キナーゼ阻害剤およびその使用方法
JP2010520293A (ja) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
WO2009071895A1 (fr) 2007-12-04 2009-06-11 Ucb Pharma S.A. Dérivés thiazole et thiophène fusionnés comme inhibiteurs de kinase
WO2009157196A1 (fr) 2008-06-25 2009-12-30 武田薬品工業株式会社 Composé amide
JPWO2010027002A1 (ja) 2008-09-05 2012-02-02 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
US20100152160A1 (en) 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
EP2415767B1 (fr) 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
MX2011013667A (es) 2009-06-25 2012-03-06 Amgen Inc Compuestos heterociclicos y sus usos.
WO2011143495A1 (fr) 2010-05-13 2011-11-17 Amgen Inc. Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012068106A2 (fr) 2010-11-15 2012-05-24 Exelixis, Inc. Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
WO2012068096A2 (fr) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs méthodes d'utilisation et de fabrication
CN102731525A (zh) * 2011-04-08 2012-10-17 上海艾力斯医药科技有限公司 苯并吗啉衍生物
IN2014CN04174A (fr) 2011-12-22 2015-09-04 Novartis Ag
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式

Also Published As

Publication number Publication date
HUE036953T2 (hu) 2018-08-28
JP2015506344A (ja) 2015-03-02
NZ624872A (en) 2015-07-31
EP2794600A1 (fr) 2014-10-29
IN2014CN04174A (fr) 2015-09-04
CY1119939T1 (el) 2018-12-12
PH12014501417A1 (en) 2014-09-22
CU20140072A7 (es) 2014-10-02
US20160106753A1 (en) 2016-04-21
WO2013093849A1 (fr) 2013-06-27
JO3398B1 (ar) 2019-10-20
ES2661864T3 (es) 2018-04-04
MA37142B1 (fr) 2019-07-31
KR101656592B1 (ko) 2016-09-23
MX2014007687A (es) 2014-07-30
HRP20180384T1 (hr) 2018-04-06
US9763952B2 (en) 2017-09-19
NO2809782T3 (fr) 2018-01-20
CR20200286A (es) 2020-09-23
CR20140294A (es) 2014-08-13
EP2794600B1 (fr) 2017-12-06
US9539260B2 (en) 2017-01-10
MY170922A (en) 2019-09-18
PL2794600T3 (pl) 2018-06-29
EA201491247A1 (ru) 2014-09-30
US20130165436A1 (en) 2013-06-27
AR089424A1 (es) 2014-08-20
CN104011045A (zh) 2014-08-27
BR112014015103B1 (pt) 2022-06-28
AU2012356083A1 (en) 2014-06-26
JP5903499B2 (ja) 2016-04-13
AP2014007658A0 (en) 2014-05-31
CN104011045B (zh) 2016-08-24
RS56891B1 (sr) 2018-04-30
CA2859764A1 (fr) 2013-06-27
MX353342B (es) 2018-01-08
KR20140107500A (ko) 2014-09-04
PT2794600T (pt) 2018-03-13
EA025322B1 (ru) 2016-12-30
LT2794600T (lt) 2018-02-26
IL233117A0 (en) 2014-07-31
UY34541A (es) 2013-09-02
UA112558C2 (uk) 2016-09-26
PE20141598A1 (es) 2014-11-14
AP4055A (en) 2017-03-07
MA37142A2 (fr) 2016-07-29
SG11201402237WA (en) 2014-09-26
TWI577674B (zh) 2017-04-11
TN2014000210A1 (en) 2015-09-30
IL233117A (en) 2017-02-28
TW201333000A (zh) 2013-08-16
GT201400131A (es) 2015-06-02
CO6990717A2 (es) 2014-07-10
PH12014501417B1 (en) 2014-09-22
BR112014015103A2 (pt) 2020-10-27
ECSP14009999A (es) 2018-10-31
SI2794600T1 (en) 2018-03-30
CA2859764C (fr) 2019-12-31
CL2014001452A1 (es) 2014-10-24
DK2794600T3 (en) 2018-03-12
AU2012356083B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA35086B1 (fr) Compose de triazolopyridine
MA37959A2 (fr) Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA35833B1 (fr) Dérivés de bétuline
EA201290632A1 (ru) Производные бетулина
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA39707A (fr) Dérivés de 1,2-dihydro-3h-pyrrolo [1,2-c]imidazol-3-one et leur utilisation comme agents antibactériens
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA31229B1 (fr) Composés de 6-benzyl-2, 3,4, 7-tétrahydro-indolo [2, 3-c] quinoline utiles en tant qu'inhibiteurs de pde5
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
UA107455C2 (uk) Похідні індолу як протиракові агенти
MA37896A1 (fr) Azahétérocycles utilisés comme inhibiteurs de bir2 et/ou bir3
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations